Key Identity Verification Trends for 2025: Regula's Expert Insights
21.1.2025 14:30:00 CET | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, unveils its vision for the identity verification (IDV) industry in 2025. As new and persistent threats converge with evolving regulations and user expectations, they bring to life new requests for significant technological advancements in IDV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121753818/en/
Regula's experts share their insights into how identity verification will evolve in 2025 (Graphic: Regula)
Threats shaping the IDV landscape
The rise in identity fraud over the past two years has significantly impacted all industries, especially Finance, Banking, FinTech, and Crypto. With deepfakes threatening every second company around the world, businesses won’t be able to stand out without liveness checks, both for biometrics and documents. However, organizations can’t blindly rely on this method as-is. They will have to introduce signal source control viahardware-enabled solutions. With deepfakes being so deeply realistic now, humans often fail to distinguish between what is fake and what is real. That is why checking signal source integrity is crucial, as it helps ensure that no injection is done during the video session within the IDV process.
Also, businesses will further reinforce their biometric verification methods, such as facial recognition, fingerprint scanning, and voice identification, as they add additional defense.
Interestingly, traditional threats like fake IDs and synthetic fraud still account for the majority of identity fraud attempts. This highlights the need for businesses to balance preparing for sophisticated future attacks with addressing the more prevalent threats of today.
Regulations and user expectations: Growing demand and pressure
The IDV landscape is evolving due to stricter laws, rising user expectations, and new workforce demands. Governments are enforcing tighter age verification to protect minors and regulate restricted services. This will be driving further technologies like biometric age estimation.
Users seek fast, personalized IDV solutions, while businesses require flexible systems. So, the IDV industry will continue developing toward user-centric design, where convenience and personalization are prioritized.
Additionally, a new IDV user category is emerging: the workforce. In the era of remote and hybrid work, identity verification for employees is critical to prevent fraud, such as fake identities and ghost employees.
Technological shifts
The evolving challenges of fraud, compliance, and user demands are driving advancements in IDV technologies and the adoption of new digital identity documentslike the Digital Travel Credential (DTC), mobile driver’s licenses (mDLs), digital identity, etc.
To ensure more efficient fraud prevention, identity verification will extend beyond traditional document and biometric checks to include additional methods, such as direct validation against governments’ or issuing authorities’ databases. Also, IDV technologies will be more deeply integrated with other IT solutions deployed in organizations to create secure ecosystems.
Journey Time Orchestration (JTO) is gaining traction, offering a dynamic platform approach to managing identity tasks across the user journey by unifying biometrics, passwords, and third-party systems to balance security and convenience.
Last but not least, AI and ML technologies will be gaining momentum in identity verification. They have been used in IDV solutions for some time already, but their influence will become more tangible as AI-generated fraud evolves into a very significant threat to businesses worldwide.
“The identity verification industry is driven by the multiple forces of advanced threats, rising user demands, tightening regulation, and technological advancements. As we move into 2025, the challenge will be to create solutions that not only address sophisticated fraud but also prioritize user convenience and regulatory compliance,” said Ihar Kliashchou, Chief Technology Officer at Regula.
To get more insights on the trends that will shape IDV in the coming year, read our blog article.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121753818/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom